NervGen Pharma (NGEN) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $18.00 | Jul 14, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $10.00 | Jul 13, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $18.00 | Apr 27, 2026 |
Frequently asked questions
Is NGEN a buy, sell, or hold?
Analysts covering NervGen Pharma currently average a Buy rating: 6 buy, 0 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NGEN?
On Jul 14, 2026, HC Wainwright & Co. maintained NervGen Pharma at Buy with a price target of $15.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.